| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9346117 | Ophthalmology | 2005 | 7 Pages |
Abstract
After ruthenium brachytherapy for uveal melanoma, the survival rates and visual outcomes in this population-based investigation were similar to previously published results. The eye was retained in 81.7% of patients. Careful patient selection (presently we only treat melanomas 7 mm or smaller in height) and life-long monitoring for recurrences is warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Louise MD, Bo BSc, Göran MD, PhD, Marie PhD, Stefan MD, PhD,